Immunohistochemical analysis of interleukin-β-converting enzyme/Ced-3 family protease, CPP32/Yama/Caspase-3, in Hodgkin's disease

Blood

Volumn 90, Issue 6, 1997, Pages 2451-2455

  Chhanabhai, Mukesh ^b   Krajewski, Stanislaw ^b   Krajewska, Maryla ^b   Wang, Hong Gang ^b   Reed, John C ^b   Gascoyne, Randy D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; INTERLEUKIN 1BETA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ARTICLE; CAENORHABDITIS ELEGANS; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME SPECIFICITY; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REED STERNBERG CELL;

EID: 0030823840     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.6.2451     Document Type: Article

References (40)

1. Reed J: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124:1, 1994
2. Boise LH, Thompson CB: Hierarchial control of lymphocyte survival. Science 274:67, 1996
3. Jacobson MD, Evan GI: Apoptosis. Breaking the ICE. Curr Biol 4:337, 1994
4. Steller H: Mechanisms and genes of cellular suicide. Science 267:1445, 1995
5. Alnemri ES, Livingston DJ, Nicholson DW, Salveson G, Thornberry NA, Wong WW, Yuan J: Human ICE/CED-3 protease nomenculture. Cell 87:171, 1996 (letter)
6. Yang E, Korsmeyer SJ: Molecular thanatopsis: A discourse on the BCL2 family and cell death. Blood 88:386, 1996
7. Yuan J, Shaham S, Ledoux S, Ellis HM, Horvitz HR: The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme. Cell 75:641, 1993
8. Xue D, Shaham S, Horvitz HR: The Caenorhabditis elegans cell-death protein CED-3 is a cysteine protease with substrate specificities similar to those of the human CPP32 protease. Genes Dev 10:1073, 1996
9. Datta R, Banach D, Kojima H, Talanian RV, Alnemri ES, Wong WW, Kufe DW: Activation of the CPP32 protease in apoptosis induced by 1-β-D-arabinofuranosylcytosine and other DNA damaging agents. Blood 88:1936, 1996
10. Fernandes-Alnemeri T, Takahashi A, Armstrong R, Krebs J, Fritz L, Tomaselli KJ, Wang L, Yu Z, Croce CM, Salveson G, Earnshaw WC, Litwack G, Alnemeri ES: Mch3, a novel human apoptotic cysteine protease highly related to CPP32. Cancer Res 55:6045, 1995
11. Krajewska M, Hong-Gang W, Krajewski S, Zapata J, Shabaik A, Gascoyne R, Reed JC: Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. Cancer Res 57:1605, 1997
12. Krajewski S, Gascoyne RD, Zapata JM, Krajewska M, Kitada S, Chhanabhai M, Horsman D, Berean K, Piro LD, Fugier-Vivier I, Lui Y, Wang H, Reed JC: Immunolocalization of the ICE/Ced-3-family protease, CPP32/Yama, in Non-Hodgkin's lymphomas, chronic lymphocytic leukemia (CLL), and reactive lymph nodes. Blood 89:3817, 1997
13. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin TT, Yu VL, Miller DK: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37, 1995
14. Armstrong RC, Aja T, Xiang J, Gaur S, Krebs JF, Hoang K, Bai X, Korsmeyer SJ, Karanewsky DS, Fritz LC, Tomaselli: Fas-induced activation of the cell death-related protease CPP32 is inhibited by Bcl-2 and by ICE family protease inhibitors. J Biol Chem 271:16850, 1996
15. Schlegel J, Peters I, Orrenius S, Miller DK, Thornberry NA, Yamin TT, Nicholson DW: CPP32/apopain is a key interleukin 1β converting enzyme-like protease involved in Fas-mediated apoptosis. J Biol Chem 271:1841, 1996
16. Enari M, Talanian RV, Wong WW, Nagata S: Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis. Nature 380:723, 1996
17. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM: Yama/CPP32b, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase. Cell 81:801, 1995
18. Mason DY, Banks PM, Chan J, Cleary ML, Delsol G, de Wolf Peeters C, Falani B, Gatter K, Grogan TM, Harris NL, Isaacson PG, Jaffe ES, Knowles DM, Muller-Hermelink K, Pileri S, Ralfkiaer E, Stein H, Warnke R: Nodular lymphocyte predominant Hodgkin's disease. A distinct clinicopathological entity. Am J Surg Pathol 18:526, 1994
19. Regula Jr DP, Hoppe RT, Weiss LM: Nodular and diffuse lymphocyte predominant Hodgkin's disease. N Engl J Med 318:214, 1988
20. Sextro M, Diehl V, Franklin J, Hansmann M-L, Anagnostopoulos I, Marafioti T, Stein H: Lymphocyte predominant Hodgkin's disease - A workshop report. Annals Oncol 7:61, 1996 (suppl 14)
21. Pappa VI, Norton AJ, Gupta RK, Wilson AM, Rohatiner AZS, Lister TA: Nodular lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases. Annals Oncol 6:559, 1995
22. Tefferi A, Zellers RA, Banks PM, Therneau TM, Colgan JP: Clinical correlates of distinct immunophenotypic and histologic subcatergories of lymphocyte predominant Hodgkin's disease. J Clin Oncol 8:1959, 1990
23. Borg-Grech A, Radford JA, Crowther D, Swindell R, Harris M: A comparative study of the nodular and diffuse variants of lymphocyte-predominant Hodgkin's disease. J Clin Oncol 7:1303, 1989
24. Capaccioli S, Quattrone A, Schiavone N, Calastretti A, Copreni E, Bevilacqua A, Canti G, Gong L, Morelli S, Nicolin A: A bcl-2/IgH antisense transcript deregulates bcl-2 expression in human follicular lymphoma cell lines. Oncogene 13:105, 1996
25. Gupta RK, Lister TA, Bodmer JG: The t(14;18) chromosomal translocation and Bcl-2 protein expression in Hodgkin's disease. Leukemia 8:1337, 1994
26. Bhagat SKM, Medeiros LJ, Weiss LM, Wang J, Raffeld M, Stetler-Stevenson: bcl-2 expression in Hodgkin's disease. Correlation with the t(14;18) translocation and Epstein-Barr virus. Am J Clin Pathol 99:604, 1993
27. Alkan S, Ross CW, Hanson CA, Schnitzer B: Epstein-Barr virus bcl-2 protein overexpression are not detected in the neoplastic cells of nodular lymphocyte predominance Hodgkin's disease. Mod Pathol 8:544, 1995
28. Brousset P, Benharroch D, Krajewski S, Laurent G, Meggetto F, Rigal-Huguet F, Gopas J, Prinsloo I, Pris J, Delsol G, Reed JC, Schlaifer D: Frequent expression of the cell death-inducing gene Bax in Reed-Sterberg cells of Hodgkin's disease. Blood 87:2470, 1996
29. Schlaifer D, March M, Krajewski S, Laurent G, Pris J, Delsol G, Reed JC, Brousset P: High expression of the bcl-x gene in Reed-Sternberg cells of Hodgkin's disease. Blood 85:2671, 1995
30. Schlaifer D, Krajewski S, Rigal-Huguet F, Laurent G, Pris J, Delsol G, Reed JC, Brousset P: Bcl-x gene expression in Hodgkin's disease. Leuk Lymphoma 23:143, 1996
31. Shimizu S, Eguchi Y, Kamiike W, Matsuda H, Tsujimoto Y: Bcl-2 expression prevents activation of the ICE protease cascade. Oncogene 12:2251, 1996
32. Monney L, Otter I, Olivier R, Ravn U, Mirzasaleh H, Fellay I, Poirier GG, Borner C: Bcl-2 overexpression blocks activation of the death protease CPP32/Yama/apopain. Biochem Biophys Res Commun 221:340, 1996
33. Boulakia CA, Chen G, Ng FWH, Teodora JG, Branton PE, Nicholson DW, Poirier GG, Shore GC: Bcl-2 and adenovirus E1B 19 kDA protein prevent E1A-induced processing of CPP32 and cleavage of poly (ADP-ribose) polymerase. Oncogene 12:529, 1996.
34. L overexpression inhibits Taxol-induced Yama protease activity and apoptosis. Cell Growth Differ 7:1087, 1996
35. L inhibits Ara-C induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res 56:4743, 1996
36. L function upstream of the CED-3-like apoptotic proteases. J Biol Chem 271:4573, 1996
37. Chinnaiyan AM, O'Rourke K, Lane BR, Dixit VM: Interaction of CED-4 with CED-9: A molecular framework for cell death. Science 275:1122, 1997
38. Wu D, Wallen HD, Nunez G: Interaction and regulation of subcellular localization of CED-4 by CED-9. Science 275:1126, 1997
39. Spector MS, Desnoyers S, Hoeppner DJ, Hengartner MO: Interaction between the C elegans cell-death regulators CED-9 and CED-4. Nature 385:653, 1997
40. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of human bax gene. Cell 80:293, 1995